Loading...
Loading...
Teva Pharmaceutical Industries
TEVA and Mylan Inc.
MYL
today announce that certain of their affiliates have agreed to settle
and dismiss pending patent litigation involving Copaxone® (glatiramer
acetate) in the United Kingdom, the Netherlands and France relating to
non-infringement and the validity of European Patent 0,762,888, which
expires in May 2015. The terms of the settlement are confidential.
About Teva
Teva Pharmaceutical Industries Ltd.
TEVA is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in